Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice

Experimental and Therapeutic Medicine

Volumn 9, Issue 1, 2015, Pages 105-111

  Zhang, Xiao Qian ^a   Zhang, Hong Mei ^a   Sun, Xiu E ^a   Yuan, Zhou Jie ^a   Feng, Yu Guang ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; ATP binding cassette transporter G2; Celecoxib; Gastric cancer; Hypoxia inducible factor 2 ; Nude mice; Octamer binding transcription factor 4

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CELECOXIB; CELL MARKER; DNA POLYMERASE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84919449809     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2077     Document Type: Article

References (33)

1. Cunningham D, Allum WH, et al: Magic Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
2. Longley DB, Harkin DP and Johnston PG. 5 -Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
3. Mathew ST, Devi SG, Prasanth VV and Vinod B. Efficacy and safety of COX-2 inhibitors in the clinical management of arthritis: Mini review. ISRN Pharmacol 2011: 480-291, 2011.
4. Dannenberg AJ and Subbaramaiah K. Targeting cyclooxy genase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
5. Schönthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 97: 1465-1468, 2007.
6. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA and Schönthal AH. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 7: 38, 2008.
7. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
8. Agboola O: Adjuvant treatment in gastric cancer. Cancer Treat Rev 20: 217-240, 1994.
9. Cunningham D, Allum WH, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
10. Longley DB, Harkin DP and Johnston PG: 5 -fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
11. Yoshida K, Yamaguchi K, et al: Challenge for a better combination with basic evidence. Int J Clin Oncol 13: 212-219, 2008.
12. Mao-Lin Jin: New progress in advanced gastric cancer systemic chemotherapy. Waike Lilun Yushijian 8: 18-20, 2003 (In Chinese).
13. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-l11, 2001.
14. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006.
15. Bertout JA, Patel SA and Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975, 2008.
16. Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102: 1276-1283, 2010.
17. Martin CM, Ferdous A, Gallardo T, et al: Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res 102: 998-1001, 2008.
18. Nichols J, Zevnik B, Anastassiadis K, et al: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95: 379-391, 1998.
19. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502, 2005.
20. Covello KL, Kehler J, Yu H, et al: HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006.
21. Dallas NA, Xia L, Fan F, et al: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69: 1951-1957, 2009.
22. Zhang XQ, Feng YG and Wu MY: Effect of 5-Fu on the ratio of SP cells and expression of HIF-2α and ABCG2 in human gastric cancer cell line SGC7901 under hypoxia. World Chinese Journal of Digestology 20: 1813-1818, 2012 (In Chinese).
23. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
24. Kuo CH, Hu HM, Tsai PY, Wu IC, Yang SF, Chang LL, Wang JY, Jan CM, Wang WM and Wu DC: Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol 15: 4907-4914, 2009.
25. Rocha FT, Lourenço LG, Jucá MJ, Costa V and Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras 24: 189-194, 2009.
26. Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemo therapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. Int J Cancer 115: 484-492, 2005.
27. Ding H, Han C, Zhu J, Chen CS and D'Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113: 803-810, 2005.
28. Li Q, Peng J and Zhan GY: Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33: 1123-1128, 2008 (In Chinese).
29. Kim N, Kim CH, Ahn DW, et al: Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 24: 480-487, 2009.
30. Wang Z, Chen H and Xia GH: Study on celecoxib inducing gastric cancer cell apoptosis and its mechanism. Journal of Modern Oncology 17: 416-420, 2009 (In Chinese).
31. Swamy MV, Herzog CR and Rao CV: Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 63: 5239-5242, 2003.
32. Erkinheimo TL, Lassus H, et al: Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu,and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10: 538-545, 2004.
33. Krysan K, Merchant FH, et al: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18: 206-208, 2004.